B Group Inc. Buys Shares of 629,370 Sight Sciences, Inc. (NASDAQ:SGHT)

B Group Inc. purchased a new position in shares of Sight Sciences, Inc. (NASDAQ:SGHT) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 629,370 shares of the company’s stock, valued at approximately $2,291,000. Sight Sciences accounts for about 1.4% of B Group Inc.’s investment portfolio, making the stock its 9th biggest holding. B Group Inc. owned 1.24% of Sight Sciences at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of the business. Dimensional Fund Advisors LP increased its stake in Sight Sciences by 79.4% during the 4th quarter. Dimensional Fund Advisors LP now owns 243,954 shares of the company’s stock worth $887,000 after purchasing an additional 108,001 shares in the last quarter. Marshall Wace LLP acquired a new stake in shares of Sight Sciences during the fourth quarter worth $96,000. Barclays PLC lifted its position in Sight Sciences by 11.9% in the 4th quarter. Barclays PLC now owns 56,294 shares of the company’s stock valued at $205,000 after acquiring an additional 5,994 shares in the last quarter. Renaissance Technologies LLC boosted its stake in Sight Sciences by 654.3% in the 4th quarter. Renaissance Technologies LLC now owns 393,006 shares of the company’s stock worth $1,431,000 after purchasing an additional 340,906 shares during the period. Finally, Dynamic Technology Lab Private Ltd bought a new position in Sight Sciences during the 4th quarter worth about $40,000. Institutional investors own 55.51% of the company’s stock.

Insider Transactions at Sight Sciences

In other news, EVP Manohar K. Raheja purchased 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, March 12th. The stock was acquired at an average cost of $2.73 per share, with a total value of $27,300.00. Following the acquisition, the executive vice president now owns 145,000 shares in the company, valued at approximately $395,850. This trade represents a 7.41 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Paul Badawi sold 24,174 shares of the company’s stock in a transaction on Tuesday, April 1st. The shares were sold at an average price of $2.30, for a total value of $55,600.20. Following the completion of the transaction, the chief executive officer now directly owns 6,010,580 shares in the company, valued at approximately $13,824,334. This represents a 0.40 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 35,196 shares of company stock worth $81,001 over the last quarter. Company insiders own 28.90% of the company’s stock.

Sight Sciences Stock Up 1.9 %

SGHT opened at $2.66 on Monday. The stock’s fifty day simple moving average is $2.56 and its 200 day simple moving average is $3.50. Sight Sciences, Inc. has a 1-year low of $2.03 and a 1-year high of $8.45. The stock has a market cap of $136.55 million, a PE ratio of -2.61 and a beta of 2.46. The company has a current ratio of 10.18, a quick ratio of 9.74 and a debt-to-equity ratio of 0.36.

Sight Sciences (NASDAQ:SGHT) last issued its quarterly earnings data on Wednesday, March 5th. The company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.01). The company had revenue of $19.07 million during the quarter, compared to the consensus estimate of $18.98 million. Sight Sciences had a negative net margin of 63.30% and a negative return on equity of 47.28%. During the same period in the previous year, the company earned ($0.22) earnings per share. As a group, research analysts expect that Sight Sciences, Inc. will post -0.99 earnings per share for the current year.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on the company. Stifel Nicolaus dropped their target price on Sight Sciences from $5.00 to $4.00 and set a “buy” rating on the stock in a research report on Thursday, March 6th. Lake Street Capital lowered their price objective on shares of Sight Sciences from $3.00 to $2.50 and set a “hold” rating on the stock in a report on Thursday, March 6th. Citigroup reduced their target price on shares of Sight Sciences from $4.60 to $3.00 and set a “neutral” rating for the company in a report on Tuesday, March 4th. Piper Sandler lowered their price target on shares of Sight Sciences from $5.50 to $3.50 and set a “neutral” rating on the stock in a research note on Thursday, March 6th. Finally, UBS Group decreased their price target on Sight Sciences from $5.50 to $5.00 and set a “buy” rating for the company in a research note on Monday, January 27th. Five analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $3.83.

Sight Sciences Company Profile

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.